Scope of this summary
Children and adults with suspected acute anaphylaxis and patients needing post-event risk reduction. The 2023 AAAAI/ACAAI practice parameter complements rather than replaces the focused 2020 GRADE work. This page does not provide product-specific autoinjector dosing, a perioperative or infusion-reaction protocol, venom or food immunotherapy selection, or a substitute for emergency response systems.
The Bottom Line
- Recognize anaphylaxis clinically and give intramuscular epinephrine promptly in the mid-outer thigh when it is suspected; treatment must not wait for hypotension, skin findings, laboratory confirmation or fulfillment of every diagnostic criterion.
- Repeat epinephrine and escalate resuscitation according to clinical response while positioning safely, supporting airway and oxygenation and giving intravenous fluid for shock; inhaled bronchodilator and other measures are adjuncts rather than substitutes.
- Do not rely on antihistamines or systemic corticosteroids to treat airway or circulatory compromise or to prevent a biphasic reaction; their use must never delay epinephrine.
- Before discharge, assess recurrence and severity risk, supply and teach appropriate epinephrine self-treatment, provide a written action plan, address the likely trigger and arrange allergy follow-up when indicated.
Practical clinical workflow
1
Call for emergency help, remove an ongoing trigger when safe, assess airway, breathing, circulation, mental status and skin or mucosal findings and record the time of symptom onset and every treatment.
2
Administer intramuscular epinephrine immediately, reassess frequently and repeat when airway, breathing or circulatory features persist; place the patient recumbent with legs elevated when tolerated and adapt position for respiratory distress, vomiting or pregnancy.
3
Establish monitoring and vascular access for significant reactions, provide oxygen and rapid isotonic fluid for hypotension, and involve advanced airway or critical-care expertise early when swelling, hypoxia or shock is progressing.
4
Individualize observation and emergency-medical-services advice from severity, treatment response, recurrence, comorbidity, distance from care and ability to recognize and treat recurrence rather than applying one duration to every patient.
Safety boundaries and escalation
- There is no absolute contraindication to intramuscular epinephrine for life-threatening anaphylaxis; concern about transient tachycardia or hypertension must not displace treatment of airway obstruction or shock.
- Persistent hypotension, hypoxia, stridor, severe bronchospasm, altered consciousness, recurrent symptoms or repeated epinephrine need requires emergency transport and higher-acuity care.
- A normal tryptase does not exclude anaphylaxis, and a raised value supports but does not independently establish the diagnosis; obtain acute and baseline testing selectively without delaying treatment.
- Review autoinjector technique, expiry and access barriers and explain when to activate emergency services, particularly for severe, incomplete, recurrent or non-durable response after self-treatment.
Localization
The 2023 Joint Task Force parameter is the named US specialty source and includes nuanced shared decision-making about emergency-services activation after community epinephrine; local EMS capability and state school or stock-epinephrine law still apply.
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- AAAAI/ACAAI Joint Task Force on Practice ParametersAnaphylaxis: A 2023 Practice Parameter UpdateDOI 10.1016/j.anai.2023.09.015 路 published online 2023-12-18; print issue February 2024 路 published 2023-12-18 路 accessed 2026-08-20view source
- AAAAI/ACAAI Joint Task Force on Practice ParametersAnaphylaxis鈥擜 2020 Practice Parameter Update, Systematic Review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) AnalysisDOI 10.1016/j.jaci.2020.01.017 路 published online 2020-01-28; print issue April 2020 路 published 2020-01-28 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.